Nuclide
Start here

Landscape grid

Count what exists where. Pick what to count and how to slice it: rows by cancer, columns by target or modality, cells showing how many products (or trials, or technologies) sit at the intersection and the best evidence tier among them. Click a count to open the list.

100 products · 29 × 8
Indication \ ModalityImaging agentRadiopharmaceuticalOtherSmall moleculeAntibodyChemotherapyDegrader or glueBispecific antibodyTotal
Prostate cancer10743·2·127
Neuroendocrine tumours4713····15
Metastatic castration-resistant prostate cancer1513·2··12
Hepatocellular carcinoma··332···8
Pancreatic neuroendocrine tumours421·····7
Thyroid cancer·114····6
Coronary artery disease3·3·····6
Renal cell carcinoma1··41···6
Small intestinal neuroendocrine tumours321·····6
Metastatic pheochromocytoma and paraganglioma1211····5
Glioma & glioblastoma4····1··5
Non-small cell lung cancer41······5
Metastatic hormone-sensitive prostate cancer·1·2·1··4
Cardiac sarcoidosis2·2·····4
Localised prostate cancer, high and very high risk1·11····3
Biochemical recurrence of prostate cancer1·11····3
Neuroblastoma·11·····2
Grade 3 well-differentiated neuroendocrine tumour·2······2
Small-cell lung cancer·1··1···2
HER2-positive breast cancer1·····1·2
Pheochromocytoma and paraganglioma1·1·····2
Lung neuroendocrine tumours1··1····2
Follicular lymphoma··1·1···2
Pulmonary embolism: ventilation/perfusion imaging··2·····2
High-risk neuroblastoma·1······1
Intermediate hepatocellular carcinoma····1···1
Non-metastatic castration-resistant prostate cancer···1····1
Diffuse large B-cell lymphoma····1···1
Cardiac amyloidosis··1·····1
Cell colour = best evidence tier in the cell:approvedphase 3 / positiveestablishedphase 2 / recruitingphase 1 / emergingpreclinicalClick a count to open the filtered list, or a cancer, target or company name to open its page. Hover for the ids. Columns capped at 24 by frequency.